Novel malonamide derivatives as potent κ opioid receptor agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 7, 2007, Pages 1951-1955

  Chu, Guo Hua ^a   Gu, Minghua ^a   Cassel, Joel A ^a   Belanger, Serge ^a   Graczyk, Thomas M ^a   DeHaven, Robert N ^a   Conway James, Nathalie ^a   Koblish, Michael ^a   Little, Patrick J ^a   DeHaven Hudkins, Diane L ^a   Dolle, Roland E ^a  

^a ADOLOR CORPORATION   (United States)

Author keywords

Agonist; Analgesic; Opioid

Indexed keywords

3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; ACETAMIDE DERIVATIVE; KAPPA OPIATE RECEPTOR AGONIST;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; NOCICEPTION; NONHUMAN; STRUCTURE ACTIVITY RELATION; WRITHING TEST;

CHEMISTRY, PHARMACEUTICAL; CYTOCHROME P-450 CYP2D6; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MALONATES; MODELS, CHEMICAL; MOLECULAR CONFORMATION; RECEPTORS, OPIOID, KAPPA;

EID: 33847620336     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.053     Document Type: Article

References (29)

1. DeHaven-Hudkins D.L., and Dolle R.E. Curr. Pharm. Des. 10 (2004) 743
2. Holzgrabe U., and Brand W. J. Med. Chem. 46 (2003) 1383
3. Soukara S., Maier C.A., Predoiu U., Ehret A., Jackisch R., and Wünsch B. J. Med. Chem. 44 (2001) 2814
4. Szmuszkovicz J., and Von Voigtlander P.F. J. Med. Chem. 25 (1982) 1225
5. Szmuszkovicz J. Prog. Drug Res. 52 (1999) 168
6. Szmuszkovicz J. Prog. Drug Res. 53 (1999) 3
7. Costello G.F., James R., Shaw J.S., Slater A.M., and Stutchbury N.C.J. J. Med. Chem. 34 (1991) 181
8. Kumar V., Guo D., Cassel J.A., Daubert J.D., DeHaven R.N., DeHaven-Hudkins D.L., Gauntner E.K., Gottshall S.L., Greiner S.L., Koblish M., Little P.J., Mansson E., and Maycock A.L. Bioorg. Med. Chem. Lett. 15 (2005) 1091
9. Tuthill P.A., Seida P.R., Barker W., Cassel J.A., Belanger S., DeHaven R.N., Koblish M., Gottshall S.L., Little P.J., DeHaven-Hudkins D.L., and Dolle R.E. Bioorg. Med. Chem. Lett. 14 (2004) 5693
10. Giardina G., Clarke G.D., Grugni M., Sbacchi M., and Vecchietti V. Farmaco 50 (1995) 405
11. Barber A., and Gottschlich R. Expert Opin. Investig. Drugs 6 (1997) 1351
12. Stein C., Machelska H., Binder W., and Schafer M. Curr. Opin. Pharmacol. 1 (2001) 62
13. Rivière P.J.-M. Br. J. Pharmacol. 141 (2004) 1331
14. Chu G.-H., Gu M.H., Cassel J.A., Belanger S., Graczyk T.M., DeHaven R.N., Conway-James N., Koblish M., Little P.J., DeHaven-Hudkins D.L., and Dolle R.E. Bioorg. Med. Chem. Lett. 15 (2005) 5114
15. Chu G.-H., Gu M.H., Cassel J.A., Belanger S., Stabley G.J., DeHaven R.N., Conway-James N., Koblish M., Little P.J., DeHaven-Hudkins D.L., and Dolle R.E. Bioorg. Med. Chem. Lett. 16 (2006) 645
16. Le Bourdonnec B., Ajello C.W., Seida P.R., Susnow R.G., Cassel J.A., Belanger S., Stabley G.J., DeHaven R.N., DeHaven-Hudkins D.L., and Dolle R.E. Bioorg. Med. Chem. Lett. 15 (2005) 2647
17. Compounds 3-12 were evaluated as CYP2D6 inhibitors only.
18. For the synthesis of 1-(2-methylamino-(S)-2-phenyl-ethyl)-pyrrolidin-(S)-3-ol: Zhang, W. Y.; Maycock, A. L.; Kumar, V.; Gaul, F.; Chang, A.-C.; Guo, D. WO00014065, 2000.
19. Bald E., Saigo K., and Mukaiyama T. Chem. Lett. (1975) 1163
20. Hakam K., Thielmann M., Thielmann T., and Winterfeldt E. Tetrahedron 43 (1987) 2035
21. Page P.C.B., Leach D.C., Hayman C.M., Hamzah A.S., Allin S.M., and McKee V. Synlett (2003) 1025
22. General review of cytochrome P450 enzymes:. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., and Nebert D.W. Pharmacogenetics 6 (1996) 1
23. Abell A.D., Morris K.B., and Litten J.C. J. Org. Chem. 55 (1990) 5217
24. 1H NMR, LC/MS and CHN analysis.
25. Opioid receptor binding assay:. DeHaven R.N., and DeHaven-Hudkins D.L. In: Enna S.J., Williams M., Ferkany J.W., Kenakin T., Porsolt R.D., and Sullivan J.P. (Eds). Current Protocols in Pharmacology (1998), John Wiley & Sons, New York 1.4.1
26. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G.I., and Reisine T. Mol. Pharmacol. 45 (1994) 330
27. 35S]GTPγS functional binding assay.
28. For a description of the in vivo nociceptive assays, see Ref. 6.
29. No data regarding brain penetration are available by now.